Audeara has moved two AI noise reduction licensing programs into commercial production, helping lift quarterly revenue 37.7% while initial orders remain modest. The milestone arrives alongside A$247,000 in cash, a A$1.292 million operating outflow and a pending A$505,000 placement tranche.
- Two AI noise reduction licensing programs enter commercial production
- Quarterly revenue rises 37.7% to A$656,747
- Operating cash outflow increases to A$1.292 million after inventory build
- A$247,000 cash held at quarter end, with A$505,000 placement tranche pending approval
- Clinico’s A$164,000 introductory Auracast orders shipped to Taiwan
AI licensing reaches commercial production
Audeara Limited (ASX:AUA) has reached a significant commercial milestone, with its first two proprietary AI noise reduction licensing programs entering commercial production. The progress is tempered by a much tighter funding position: the hearing technology company held A$247,000 in cash at 30 September after an unaudited operating cash outflow of A$1.292 million during the September quarter.
The licensing programs generated initial purchase orders of approximately A$31,000. Under the model, Audeara’s algorithms are embedded in semiconductor platforms used by third-party equipment manufacturers, allowing partners to produce and distribute the finished hardware while Audeara earns licensing revenue. The development extends the AI chip licensing milestone, which previously involved initial production orders with Optek, but the latest filing says future revenue will depend on customer production schedules, validation requirements and additional orders.
Revenue rises as receipts and cash flow weaken
Group revenue rose 37.7% from the June quarter to A$656,747, led by Australian wholesale revenue of A$525,390, up 39.2%. AUA Technology revenue increased 193.2% to A$62,195, although the smaller division’s contribution remains relatively modest in absolute terms.
Customer receipts moved in the opposite direction, falling 13% quarter on quarter to A$617,000 and 49.8% from the prior corresponding period. Audeara attributed the decline primarily to the timing of purchase orders from key AUA Technology customers. Net operating cash outflow increased from A$795,000 to A$1.292 million, which the company attributed to a strategic inventory build ahead of pending orders.
Placement provides near-term funding, subject to approval
Audeara received A$755,000 before costs from the first tranche of a two-tranche placement during the quarter. The second tranche, worth approximately A$505,000 before costs, requires shareholder approval at the 24 November annual meeting. The funding plan was announced in the A$1.26 million placement, which was intended to support licensing, engineering services, partner products, inventory and working capital.
On the quarter-end cash balance and current operating outflow, Appendix 4C calculations show 0.19 quarters of funding available. That measure excludes the pending placement tranche and assumes the quarter’s operating cash burn continues, while the company says outflows should reduce after inventory purchases and targeted research and development investment. Audeara also reported A$1.151 million of financing facilities at quarter end, all of which was drawn.
Clinico deployment adds a commercial proof point
After quarter end, Clinico fulfilled and shipped introductory Auracast orders worth approximately A$164,000 to Taiwan, where the products have been launched in a university setting. The company stressed that the donated systems placed at Chung Shan Medical University were not additional Audeara sales, and that approximately A$734,000 of cumulative Clinico purchase orders is a historical total rather than new September-quarter revenue.
Audeara is also pursuing orders through its Australian clinical and wholesale channels and partner programs involving ShokzHear, Bolton Clarke and Clinico. Its participation at EUHA 2026 in Germany generated follow-up discussions with hearing-care professionals, distributors and technology partners, but the filing provides no revenue guidance from those engagements.
December quarter must convert production into cash
The next test is straightforward but demanding: turn commercial production into repeat licensing orders while improving receipts through wholesale and partner channels. Audeara is also progressing an OTCID quotation application for potential US investor access, though acceptance is not guaranteed, and must secure approval for the second placement tranche at the November meeting.
Bottom Line?
Audeara now has a commercial licensing milestone to build on, but the next quarter needs to show that production activity can become repeat orders and cash receipts before the funding cushion is tested further.
Questions in the middle?
- Will the two AI licensing programs generate follow-on orders beyond the initial A$31,000?
- Will shareholders approve the A$505,000 second placement tranche before cash pressure intensifies?
- Can Clinico, wholesale and other partner channels produce repeat receipts at a pace that reduces operating cash burn?